11202020 :: Friday finance

Week in review

A partial digest of what we learned:

Holy vaccine, Act II.

The good news: Not only did Moderna come through with some exceptional early-look news of its own — 94.5% efficacy for their mRNA vaccine — but upon completion of the Pfizer-BioNTech study, the latter partnership’s final figure is 95% efficacy, not 90%. They have applied to the FDA for emergency authorization as of Friday, November 20.